GLK-321 high dose BID Clinical Trials (2026): 1 Studies for Demodex Blepharitis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 GLK-321 high dose BID clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Demodex Blepharitis) and 250 total planned enrollment. 1 GLK-321 high dose BID clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07400965 (Nov 2026).
Where to Participate: All GLK-321 high dose BID Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting GLK-321 high dose BIDtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Glaukos Clinical Study Site | Newport Beach92663 | NCT07400965 | Map |
GLK-321 high dose BID clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P2 | 1 | 1 |
Recruiting GLK-321 high dose BID clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07400965 | Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis | P2 | Demodex Blepharitis | 250 | Dec 2025 |
All GLK-321 high dose BID trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07400965 | Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis | P2 | recruiting | 250 | Glaukos Corporation | Dec 2025 |
GLK-321 high dose BID clinical trials: frequently asked questions
- How many GLK-321 high dose BID clinical trials are there?
- 1 GLK-321 high dose BID clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are GLK-321 high dose BID clinical trials recruiting in 2026?
- Yes — 1 GLK-321 high dose BID trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is GLK-321 high dose BID being studied for?
- GLK-321 high dose BID is being studied for Demodex Blepharitis. The trials are grouped by indication on this page.
- What phase is GLK-321 high dose BID in?
- GLK-321 high dose BID clinical trials span 1 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors GLK-321 high dose BID clinical trials?
- The lead sponsor across the most GLK-321 high dose BID trials is Glaukos Corporation. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming GLK-321 high dose BIDas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: